Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.

Publication ,  Journal Article
Boeckh, M; Bowden, RA; Storer, B; Chao, NJ; Spielberger, R; Tierney, DK; Gallez-Hawkins, G; Cunningham, T; Blume, KG; Levitt, D; Zaia, JA
Published in: Biol Blood Marrow Transplant
2001

MSL-109 is a monoclonal antibody specific to the cytomegalovirus (CMV) glycoprotein H with high neutralizing capacity. In a prospective, randomized, double-blind study, allogeneic hematopoietic stem cell transplantation (HSCT) recipients with positive donor and/or recipient serology for CMV before transplantation received either 60 mg/kg MSL-109 (n = 59), 15 mg/kg MSL-109 (n = 60), or placebo (n = 60) intravenously every 2 weeks from day -1 until day 84 after transplantation. CMV pp65 antigenemia, CMV-DNA load in plasma, and viremia by culture were tested weekly. Primary end points were development of pp65 antigenemia at any level and/or viremia for which ganciclovir was given. There was no statistically significant difference in CMV pp65 antigenemia or viremia among patients in the 60-mg group (pp65 antigenemia, 47%; viremia, 15%), the 15-mg group (52%; 23%), and the placebo group (45%; 17%). There was also no difference in maximum levels of pp65 antigenemia, time to clearance of pp65 antigenemia after start of ganciclovir, CMV disease, invasive bacterial and fungal infections, time to neutrophil and platelet engraftment, acute graft-versus-host disease, days of hospitalization, and overall survival rate among the 3 groups. However, a subgroup analysis of CMV-seronegative recipients with a seropositive donor (D+/R-) showed a transiently improved survival rate by day 100 in MSL-109 recipients (mortality: 60-mg group, 1/13; 15-mg group, 1/12; placebo group, 6/10 [P = .02 for 60-mg versus placebo groups; P = .08 for 15-mg versus placebo groups]); by the end of follow-up, the difference was no longer statistically significant. The improved survival rate in D+/R- patients could not be attributed to a reduction in CMV disease; however, MSL-109 was associated with improved platelet engraftment and less grade III to IV acute graft-versus-host disease in this subgroup. In a subgroup analysis of CMV-seropositive recipients of MSL-109 (D+/R+ and D-/R+), overall mortality was increased compared to that of the placebo group (P = .12 for the 60-mg versus placebo groups, P = .05 for the 15-mg versus placebo groups, and P = .04 for the dose levels combined versus placebo). MSL-109 was well tolerated and no immune response to the drug was observed. Thus, MSL-109 was safe but did not reduce CMV infection in allogeneic HSCT recipients. The transient survival advantage seen early after transplantation in CMV D+/R- patients and the negative effect on survival in seropositive patients remain unexplained. Thus, there is no evidence that MSL-109 is beneficial in CMV-seropositive HSCT recipients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Biol Blood Marrow Transplant

DOI

ISSN

1083-8791

Publication Date

2001

Volume

7

Issue

6

Start / End Page

343 / 351

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Transplantation, Homologous
  • Survival Rate
  • Prospective Studies
  • Placebos
  • Male
  • Immunology
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Boeckh, M., Bowden, R. A., Storer, B., Chao, N. J., Spielberger, R., Tierney, D. K., … Zaia, J. A. (2001). Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 7(6), 343–351. https://doi.org/10.1016/s1083-8791(01)80005-7
Boeckh, M., R. A. Bowden, B. Storer, N. J. Chao, R. Spielberger, D. K. Tierney, G. Gallez-Hawkins, et al. “Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.Biol Blood Marrow Transplant 7, no. 6 (2001): 343–51. https://doi.org/10.1016/s1083-8791(01)80005-7.
Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, Tierney DK, Gallez-Hawkins G, Cunningham T, Blume KG, Levitt D, Zaia JA. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7(6):343–351.
Journal cover image

Published In

Biol Blood Marrow Transplant

DOI

ISSN

1083-8791

Publication Date

2001

Volume

7

Issue

6

Start / End Page

343 / 351

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Transplantation, Homologous
  • Survival Rate
  • Prospective Studies
  • Placebos
  • Male
  • Immunology
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Female